CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 174 enrolled
Drug / intervention
SAGE-718 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05619692
NCT05619692Phase 2Completed
CompareCT.gov

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease

Supernus Pharmaceuticals, Inc.·interventional·Posted Nov 17, 2022·Updated Sep 15, 2025

In Brief

A Phase 2 clinical trial evaluating SAGE-718 and SAGE-718-matching Placebo for Mild Cognitive Impairment and 2 related conditions. Completed, enrolled 174 participants across 39 sites in 2 countries.

Detailed Summary

The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance in participants with Alzheimer's Disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMild Cognitive Impairment, Mild Dementia, Alzheimer's Disease
CountriesPuerto Rico, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedNov 17, 2022
Enrollment StartNov 29, 2022
Primary CompletionJun 5, 2024
Study CompletionJul 9, 2024
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 3.6 years ago

Interventions

SAGE-718drug

Softgel lipid capsules.

SAGE-718-matching Placebodrug

Softgel lipid capsules.